61
Participants
Start Date
March 8, 2021
Primary Completion Date
December 20, 2026
Study Completion Date
December 8, 2030
Daratumumab
Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Bortezomib
Subcutaneous, dosage per protocol, dose days vary per cycle. Cycle =28 days
Lenalidomide
Oral, dosage per protocol, days 1-21 per cycle
Dexamethasone
Oral, dosage per protocol, dose days vary per cycle. Cycle =28 days
Stamford Hospital, Stamford
Brigham and Women's Hospital, Boston
Dana-Farber Cancer Institute, Boston
Dana-Farber Brigham Cancer Center - Foxborough, Foxborough
Dana-Farber Cancer Institute - Merrimack Valley, Methuen
Dana-Farber Brigham Cancer Center, South Weymouth
Collaborators (1)
Janssen Pharmaceuticals
INDUSTRY
Omar Nadeem, MD
OTHER